Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2026)

Collegium Pharmaceutical's EBITDA Margin history runs 11 years deep, the most recent figure standing at 16.2% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 339.0% year-over-year to 16.2%; the TTM figure through Mar 2026 stood at 23.77% (down 414.0% YoY), while the FY2025 annual figure was 23.55%, down 397.0% from the prior year.
• EBITDA Margin was 16.2% for Q1 2026 at Collegium Pharmaceutical, down from 29.57% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 437.62% in Q3 2024 to a low of 275.52% in Q1 2022.
• Historically, EBITDA Margin has averaged 29.9% across 5 years, with a median of 20.95% in 2024.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 40469 bps in 2024, then sank 40797 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 9.07% in 2022, then soared by 354 bps to 41.2% in 2023, then plunged by 49 bps to 20.95% in 2024, then soared by 41 bps to 29.57% in 2025, then slumped by 45 bps to 16.2% in 2026.
• The last three EBITDA Margin figures came in at 16.2% (Q1 2026), 29.57% (Q4 2025), and 29.66% (Q3 2025), per Business Quant data.